推薦產品
化驗
97%
形狀
solid
光學活性
[α]/D −1 to +1.0°, c = 1 in H2O
mp
162-169 °C (lit.)
儲存溫度
2-8°C
SMILES 字串
Cl.N[C@@H]1C[C@H]1c2ccccc2
InChI
1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m0./s1
InChI 密鑰
ZPEFMSTTZXJOTM-OULXEKPRSA-N
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
非选择性 MAO-A/B 抑制剂。
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Oral
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
Kaisa A Salminen et al.
Drug metabolism and disposition: the biological fate of chemicals, 43(12), 1891-1904 (2015-09-25)
The cytochrome P450 2C19 (CYP2C19) enzyme plays an important role in the metabolism of many commonly used drugs. Relatively little is known about CYP2C19 inhibitors, including compounds of natural origin, which could inhibit CYP2C19, potentially causing clinically relevant metabolism-based drug
James M Hill et al.
Science translational medicine, 6(265), 265ra169-265ra169 (2014-12-05)
Herpesviruses are highly prevalent and maintain lifelong latent reservoirs, thus posing challenges to the control of herpetic disease despite the availability of antiviral pharmaceuticals that target viral DNA replication. The initiation of herpes simplex virus infection and reactivation from latency
Ramakrishna Nirogi et al.
Chemico-biological interactions, 230, 9-20 (2015-02-07)
The objective of the study was to evaluate the metabolism dependent inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes by monoamine oxidase (MAO) inhibitors and to predict the drug-drug interaction potential of monoamine oxidase inhibitors as perpetrators of
Yuki Ogawa et al.
European journal of pediatrics, 174(4), 509-518 (2014-09-25)
This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
Christine R Klaus et al.
The Journal of pharmacology and experimental therapeutics, 350(3), 646-656 (2014-07-06)
EPZ-5676 [(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol], a small-molecule inhibitor of the protein methyltransferase DOT1L, is currently under clinical investigation for acute leukemias bearing MLL-rearrangements (MLL-r). In this study, we evaluated EPZ-5676 in combination with standard of care (SOC) agents for acute leukemias as well
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務